The OX51 project aims to develop a sublingual dosage form for the treatment of acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief.
Orexo intends to start the next phase of the development during the second half of 2011 following discussions with regulatory authorities.
The company currently has 3 fully owned programs (including OX51) in early stage clinical development, all directed towards hospital and specialist commercial segments.
Orexo president and CEO Anders Lundstrom said the successful outcome of this trial shows important progress for Orexo in building its proprietary pipeline.